Your browser doesn't support javascript.
loading
A Joint Statement from the European Association of Urology Renal Cell Cancer Guidelines Panel and the International Kidney Cancer Coalition: The Rejection of Ipilimumab and Nivolumab for Renal Cancer by the Committee for Medicinal Products for Human Use Does not Change Evidence-based Guideline Recommendations.
Bex, Axel; Albiges, Laurence; Staehler, Michael; Bensalah, Karim; Giles, Rachel H; Dabestani, Saeed; Hofmann, Fabian; Hora, Milan; Kuczyk, Markus A; Lam, Thomas B; Marconi, Lorenzo; Merseburger, Axel S; Fernández-Pello, Sergio; Tahbaz, Rana; Abu-Ghanem, Yasmin; Volpe, Alessandro; Ljungberg, Börje; Escudier, Bernard; Powles, Thomas.
Afiliação
  • Bex A; Department of Urology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
  • Albiges L; Department of Cancer Medicine, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
  • Staehler M; Department of Urology, Ludwig-Maximilians University, Munich, Germany.
  • Bensalah K; Department of Urology, University of Rennes, Rennes, France.
  • Giles RH; International Kidney Cancer Coalition (IKCC), Duivendrecht, The Netherlands; Department of Nephrology and Hypertension, Regenerative Medicine Center, University Medical Centre Utrecht, Utrecht, The Netherlands.
  • Dabestani S; Department of Clinical Sciences Lund, Lund University, Skåne University Hospital, Malmö, Sweden.
  • Hofmann F; Department of Urology, Sunderby Hospital, Sunderby, Sweden.
  • Hora M; Department of Urology, Faculty Hospital and Faculty of Medicine in Pilsen, Charles University in Prague, Prague, Czech Republic.
  • Kuczyk MA; Department of Urology and Urologic Oncology, Hannover Medical School, Hannover, Germany.
  • Lam TB; Department of Urology, Aberdeen Royal Infirmary, Aberdeen, UK; Academic Urology Unit, University of Aberdeen, Aberdeen, UK.
  • Marconi L; Department of Urology, Coimbra University Hospital, Coimbra, Portugal.
  • Merseburger AS; Department of Urology, University Hospital Schleswig-Holstein, Lübeck, Germany.
  • Fernández-Pello S; Department of Urology, Cabueñes Hospital, Gijón, Spain.
  • Tahbaz R; Department of Urology, Elbe Kliniken Stade, Stade, Germany.
  • Abu-Ghanem Y; Department of Urology, Chaim Sheba Medical Center, Tel-Hashomer, Ramat-Gan, Israel.
  • Volpe A; Division of Urology, Maggiore della Carita' Hospital, University of Eastern Piedmont, Novara, Italy.
  • Ljungberg B; Department of Surgical and Perioperative Sciences, Urology and Andrology, Umeå University, Umeå, Sweden.
  • Escudier B; Gustave Roussy Cancer Institute, Villejuif Cedex, France.
  • Powles T; The Royal Free NHS Trust and Barts Cancer Institute, Queen Mary University of London, London, UK. Electronic address: thomas.powles@bartshealth.nhs.uk.
Eur Urol ; 74(6): 849-851, 2018 12.
Article em En | MEDLINE | ID: mdl-30201510
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Urologia / Carcinoma de Células Renais / Protocolos de Quimioterapia Combinada Antineoplásica / Aprovação de Drogas / Medicina Baseada em Evidências / Tomada de Decisão Clínica / Ipilimumab / Antineoplásicos Imunológicos / Nivolumabe / Neoplasias Renais Tipo de estudo: Guideline / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Eur Urol Ano de publicação: 2018 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Urologia / Carcinoma de Células Renais / Protocolos de Quimioterapia Combinada Antineoplásica / Aprovação de Drogas / Medicina Baseada em Evidências / Tomada de Decisão Clínica / Ipilimumab / Antineoplásicos Imunológicos / Nivolumabe / Neoplasias Renais Tipo de estudo: Guideline / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Eur Urol Ano de publicação: 2018 Tipo de documento: Article